Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12672795 
Haller D, et al. (2003) Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J Biol Chem 278, 23851-60 12672795
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (mouse)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
bacterial infection increase
TGF-beta bacterial infection no effect upon treatment-induced increase

S11-p - H3 (mouse)
Orthologous residues
H3 (human): S11‑p, H3 (mouse): S11‑p, H3 iso2 (mouse): S11‑p, H3 iso3 (mouse): S11‑p, H3 (rat): S11‑p, H3 iso3 (rat): S11‑p, H3 (pig): S11‑p, H3 (chicken): S11‑p, H3 (cow): S11‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bacterial infection increase
TGF-beta bacterial infection inhibit treatment-induced increase
LPS increase
TGF-beta LPS inhibit treatment-induced increase
trichostatin A TGF-beta inhibit treatment-induced decrease

S32-p - IkB-alpha (mouse)
Orthologous residues
IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
bacterial infection increase
TGF-beta bacterial infection no effect upon treatment-induced increase

S534-p - NFkB-p65 (mouse)
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
bacterial infection increase
TGF-beta bacterial infection no effect upon treatment-induced increase

S433-p - Smad2 (mouse)
Orthologous residues
Smad2 (human): S433‑p, Smad2 (mouse): S433‑p, Smad2 (rat): S433‑p, Smad2 (cow): S433‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase

S465-p - Smad2 (mouse)
Orthologous residues
Smad2 (human): S465‑p, Smad2 (mouse): S465‑p, Smad2 (rat): S465‑p, Smad2 (cow): S465‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase

S467-p - Smad2 (mouse)
Orthologous residues
Smad2 (human): S467‑p, Smad2 (mouse): S467‑p, Smad2 (rat): S467‑p, Smad2 (cow): S467‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  CMT-93 (intestinal)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.